MicroRNA-33a/b in lipid metabolism – Novel “thrifty” models

Circulation Journal

Volumn 79, Issue 2, 2015, Pages 278-284

  Ono, Koh ^a   Horie, Takahiro ^a   Nishino, Tomohiro ^a   Baba, Osamu ^a   Kuwabara, Yasuhide ^a   Yokode, Masayuki ^a   Kita, Toru ^b   Kimura, Takeshi ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

Author keywords

High density lipoprotein cholesterol; Lipid homeostasis; MicroRNA

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL ESTER; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MICRORNA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; STEROL REGULATORY ELEMENT BINDING PROTEIN; 3' UNTRANSLATED REGION; ABC TRANSPORTER A1; ABCA1 PROTEIN, HUMAN; MIRN33 MICRORNA, HUMAN; SREBF1 PROTEIN, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ATHEROSCLEROSIS; BIOGENESIS; CHOLESTEROL TRANSPORT; FATTY LIVER; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID HOMEOSTASIS; LIPID METABOLISM; LIVER CLEARANCE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; RNA DEGRADATION; WESTERN BLOTTING; 3' UNTRANSLATED REGION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; RNA STABILITY;

3' UNTRANSLATED REGIONS; ANIMALS; ATHEROSCLEROSIS; ATP BINDING CASSETTE TRANSPORTER 1; GENE EXPRESSION REGULATION; HUMANS; LIPID METABOLISM; MICRORNAS; RNA STABILITY; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84928267312     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1252     Document Type: Review

References (49)

1. Bartel DP. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
2. Ambros V. The functions of animal microRNAs. Nature 2004; 431: 350–355.
3. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843–854.
4. Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993; 75: 855–862.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15–20.
6. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92–105.
7. Kozomara A, Griffiths-Jones S. MiRBase: Integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011; 39: D152–D157.
8. Chelouf S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature 2010; 465: 584–589.
9. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012; 13: 239–250.
10. Chim SS, Shing TK, Hung EC, Leung TY, Lau TK, Chiu RW, et al. Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 2008; 54: 482–490.
11. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage. Circ Cardiovasc Genet 2011; 4: 446–454.
12. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol 2011; 51: 872–875.
13. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. Circ Res 2010; 107: 677–684.
14. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. Mir423-5p as a circulating biomarker for heart failure. Circ Res 2010; 106: 1035–1039.
15. Li S, Zhu J, Zhang W, Chen Y, Zhang K, Popescu LM, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011; 124: 175–184.
16. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, et al. Expression profile of microRNAs in young stroke patients. PLoS One 2009; 4: e7689, doi:10.1371/journal.pone.0007689.
17. Moore KJ, Rayner KJ, Suarez Y, Fernandez-Hernando C. MicroRNAs and cholesterol metabolism. Trends Endocrinol Metab 2010; 21: 699–706.
18. Norata GD, Sala F, Catapano AL, Fernandez-Hernando C. MicroRNAs and lipoproteins: A connection beyond atherosclerosis? Atherosclerosis 2013; 227: 209–215.
19. Zhang B, Kawachi E, Matsunaga A, Imaizumi S, Noda K, Uehara Y, et al. Reactivity of direct assays for low-density lipoprotein (LDL) cholesterol toward charge-modified LDL in hypercholesterolemia. Circ J 2012; 76: 2241–2248.
20. Cheng AY, Leiter LA. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Curr Opin Cardiol 2006; 21: 400–404.
21. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 2004; 44: 720–732.
22. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–1504.
23. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–1435.
24. Hirayama A, Honarpour N, Yoshida M, Yamashita S, Huang F, Wasserman SM, et al. Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk: Primary results from the Phase 2 YUKAWA study. Circ J 2014; 78: 1073–1082.
25. Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, et al. Therapeutic approaches to the regulation of metabolism of high-density lipoprotein: Novel HDL-directed pharmacological intervention and exercise. Circ J 2013; 77: 2651–2663.
26. Matsue Y, Matsumura A, Suzuki M, Hashimoto Y, Yoshida M. Differences in action of atorvastatin and ezetimibe in lowering low-density lipoprotein cholesterol and effect on endothelial function: Randomized controlled trial. Circ J 2013; 77: 1791–1798.
27. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory elementbinding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010; 107: 17321–17326.
28. Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc 2012; 1: e003376, doi:10.1161/JAHA.112.003376.
29. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, et al. MicroRNA-33 regulates sterol regulatory element-binding protein 1 expression in mice. Nat Commun 2013; 4: 2883, doi:10.1038/ncomms3883.
30. Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, et al. MicroRNA-33b knock-in mice for an intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit reduced HDL-C in vivo. Sci Rep 2014; 4: 5312, doi:10.1038/srep05312.
31. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. miR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328: 1570–1573.
32. Najaf-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566–1569.
33. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 2010; 107: 12228–12232.
34. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010; 285: 33652–33661.
35. Brown MS, Ye J, Goldstein JL. Medicine: HDL miR-ed down by SREBP introns. Science 2010; 328: 1495–1496.
36. Brown MS, Goldstein JL. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331–340.
37. Horton JD, Shimomura I. Sterol regulatory element-binding proteins: Activators of cholesterol and fatty acid biosynthesis. Curr Opin Lipidol 1999; 10: 143–150.
38. Horton JD, Goldstein JL, Brown MS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125–1131.
39. Munehira Y, Ohnishi T, Kawamoto S, Furuya A, Shitara K, Imamura M, et al. Alpha1-syntrophin modulates turnover of ABCA1. J Biol Chem 2004; 279: 15091–15095.
40. Allen RM, Marquart TJ, Albert CJ, Suchy FJ, Wang DQ, Ananthanarayanan M, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med 2012; 4: 882–895.
41. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011; 121: 2921–2931.
42. Tang C, Liu Y, Kessler PS, Vaughan AM, Oram JF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009; 284: 32336–32343.
43. Marquart TJ, Wu J, Lusis AJ, Baldan A. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2013; 33: 455–458.
44. Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice: Brief report. Arterioscler Thromb Vasc Biol 2013; 33: 1973–1977.
45. Sheng Z, Otani H, Brown MS, Goldstein JL. Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. Proc Natl Acad Sci USA 1995; 92: 935–938.
46. DeBose-Boyd RA, Ou J, Goldstein JL, Brown MS. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc Natl Acad Sci USA 2001; 98: 1477–1482.
47. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819–2830.
48. Yoshikawa T, Shimano H, Amemiya-Kudo M, Yahagi N, Hasty AH, Matsuzaka T, et al. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol 2001; 21: 2991–3000.
49. Rottiers V, Obad S, Petri A, McGarrah R, Lindholm MW, Black JC, et al. Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med 2013; 5: 212ra162.